Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC

This study is a phase I/II open-label randomized clinical trial to examine whether administration of isunakinra (EBI-005), a modified recombinant IL1 receptor antagonist, can sensitize human TNBC to the PD1 inhibitor-pembrolizumab-based neoadjuvant chemotherapy (NAC/P) by changing the tumor microenvironment (TME) via reducing the recruitment of immunosuppressive tumorassociated macrophages (TAMs) and increasing activated cytotoxic T-lymphocytes (CTLs).

Trial Details

NCT ID
NCT07698106
Phase
PHASE1 / PHASE2
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Group 1-Isunakinra
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Age \> 18 years
  • Newly diagnosed, locally advanced, previously untreated and centrally confirmed TNBC, as defined by the most recent American Society of Clinical On…
  • Clinical stage T1c/N1-N2, T2-4/N0-2
  • Provides core needle biopsies consisting of at least 2 separate tumor cores from the primary tumor to the central laboratory

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →